Evidence map›Paper›PMID 39569586›Full record

ArticleNucleic acids research2024

Single-stranded DNA with internal base modifications mediates highly efficient knock-in in primary cells using CRISPR-Cas9.

Karen L Kanke, Rachael E Rayner, Jack Bozik, Eli Abel, Aparna Venugopalan, Ma Suu, Reza Nouri, Jacob T Stack, Gongbo Guo, Tatyana A Vetter and 3 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Predicting Single-Stranded DNA Oligonucleotides 3D Structures: An Open Issue.Computational and structural biotechnology journal · 2026
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Karen L KankeCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Rachael E RaynerDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA.
Jack BozikCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Eli AbelCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Aparna VenugopalanCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Ma SuuCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Reza NouriCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Jacob T StackCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Gongbo GuoInstitute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Tatyana A VetterCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Estelle Cormet-BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA.
Mark E HesterInstitute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.
Sriram VaidyanathanCenter for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43215, USA.ORCID 0000-0001-9167-3056

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
A universal genome editing strategy to develop an airway stem cell therapy for cystic fibrosisR00HL151900 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI VAIDYANATHAN, SRIRAM · 2022 to 2024
$747k
A universal genome editing strategy to develop an airway stem cell therapy for cystic fibrosisK99HL151900 · NHLBI · STANFORD UNIVERSITY · PI VAIDYANATHAN, SRIRAM · 2021 to 2022
$333k
Center for Clinical and Translational Science UL1TR002733Comprehensive Transplant Center Human Tissue Biorepository, OSU Wexner Medical CenterCystic Fibrosis Foundation VAIDYA22A0-KBNational Institute of Diabetes, Digestive and Kidney Diseases DK106829Nationwide Children's Hospital MCCOY19RoNCATS NIH HHS UL1 TR002733NHLBI NIH HHS HL151900-03NHLBI NIH HHS K99 HL151900NHLBI NIH HHS R00 HL151900NIDDK NIH HHS U54 DK106829Ohio State University
6 · The paper itself

Abstract

Single-stranded DNA (ssDNA) templates along with Cas9 have been used for knocking-in exogenous sequences in the genome but suffer from low efficiency. Here, we show that ssDNA with chemical modifications in 12-19% of internal bases, which we denote as enhanced ssDNA (esDNA), improve knock-in (KI) by 2-3-fold compared to end-modified ssDNA in airway basal stem cells (ABCs), CD34 + hematopoietic cells (CD34 + cells), T-cells and endothelial cells. Over 50% of alleles showed KI in three clinically relevant loci (CFTR, HBB and CCR5) in ABCs using esDNA and up to 70% of alleles showed KI in the HBB locus in CD34 + cells in the presence of a DNA-PKcs inhibitor. This level of correction is therapeutically relevant and is comparable to adeno-associated virus-based templates. The esDNA templates did not improve KI in induced pluripotent stem cells (iPSCs). This may be due to the absence of the nuclease TREX1 in iPSCs. Indeed, knocking out TREX1 in other cells improved KI using unmodified ssDNA. esDNA can be used to modify 20-30 bp regions in primary cells for therapeutic applications and biological modeling. The use of this approach for gene length insertions will require new methods to produce long chemically modified ssDNA in scalable quantities.

Indexed as

CRISPR-Cas SystemsDNA, Single-StrandedGene Knock-In TechniquesInduced Pluripotent Stem CellsCells, CulturedGene EditingHematopoietic Stem CellsHumansReceptors, CCR5CCR5 protein, humanDNA, Single-StrandedReceptors, CCR5

Identifiers

PMID39569586
PMCPMC11662658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.